Search
verubecestat
Contraindications:
- mild-moderate Alzheimer's disease
- does not reduce cognitive or functional decline [2]
- associated with treatment-related adverse events [2]
Dosage:
- 12, 40 & 60 mg PO QD
Mechanism of action:
- inhibits BACE1
General
enzyme inhibitor
neurologic agent
Database Correlations
PUBCHEM cid=51352361
References
- Thaisrivongs DA, Morris WJ, Tan L, Song ZJ et al
A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931).
Org Lett. 2018 Mar 16;20(6):1568-1571. Epub 2018 Feb 26.
PMID: 29481097
- Egan MF, Kost J, Tariot PN et al
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's
Disease.
N Engl J Med 2018; 378:1691-1703. May 3, 2018
PMID: 29719179
https://www.nejm.org/doi/full/10.1056/NEJMoa1706441
- Egan MF, Kost J, Voss T et al
Randomized Trial of Verubecestat for Prodromal Alzheimer's
Disease.
N Engl J Med 2019; 380:1408-1420. April 11.
PMID: 30970186
https://www.nejm.org/doi/full/10.1056/NEJMoa1812840